Abstract
Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized the treatment of hematologic malignancies. Approximately half of patients with refractory large B-cell lymphomas achieve durable responses from CD19-targeting CAR-T treatment; however, failure mechanisms are identified in only a fraction of cases. To gain novel insights into the basis of clinical response, we performed single-cell transcriptome sequencing of 105 pre- and post-treatment peripheral blood mononuclear cell samples, and infusion products collected from 32 individuals with high-grade B cell lymphoma treated with either of two CD19 CAR-T products: axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel). Expansion of proliferative memory-like CD8 clones was a hallmark of tisa-cel response, whereas axi-cel responders displayed more heterogeneous populations. Elevations in CAR-T regulatory cells (CAR-Tregs) among non-responders to axi-cel were detected, and these populations were capable of suppressing conventional CAR-T cell expansion and driving late relapses in an in vivo model. Our analyses reveal the temporal dynamics of effective responses to CAR-T therapy, the distinct molecular phenotypes of CAR-T cells with differing designs, and the capacity for even small increases in CAR-Tregs to drive relapse.
Competing Interest Statement
N.J.H. is a consultant for Constellation Pharmaceuticals. C.J.W. holds equity in BioNTech Inc and receives research funding from Pharmacyclics. S.H.G. holds patents related to adoptive cell therapies, held by University College London and Novalgen Limited. S.H.G. provides consultancy to Novalgen Ltd. G.G. receives research funds from IBM and Pharmacyclics, and is an inventor on patent applications related to MSMuTect, MSMutSig, MSIDetect, POLYSOLVER and SignatureAnalyzer-GPU. G.G. is a founder, consultant and holds privately held equity in Scorpion Therapeutics. M.V.M., M.B.L., and R.C.L. are inventors on patents related to adoptive cell therapies, held by Massachusetts General Hospital. M.V.M. is also an inventor on patents related to CAR-T cell therapies held by the University of Pennsylvania (some licensed to Novartis). M.V.M. holds equity in TCR2, Century Therapeutics, Genocea, Oncternal, and Neximmune, and has served as a consultant for multiple companies involved in cell therapies.
Funding Statement
This work was partially supported by the Broad/IBM Cancer Resistance Research Project (PIs: G.G., L.P.) and by NIH R01CA252940 (PIs: M.V.M. and G.G.). A special thank you to Dr. Silvia Arrom and Mr. David Oran for their thoughtful donation which helped to support a portion of this work. N.J.H. was partially funded by the Landry Cancer Biology Consortium fellowship. S.L. is supported by the NCI Research Specialist Award (R50CA251956). R.C.L. is supported by NIH T32 AI007529.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Office for Human Research Studies of the Dana-Farber/Harvard Cancer Center gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data produced in the present work will be made publicly available upon publication in a peer-reviewed journal.
